We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Selective Amino Acid Substitution Modifies Neurotransmitter Transporter Behavior

By Biotechdaily staff writers
Posted on 04 Jun 2007
Researchers have identified the critical amino acids that comprise the site where the neurotransmitter creatine binds to the creatine transporter, the protein responsible for import of creatine into brain cells.

Creatine is a naturally occurring compound that is produced by the liver from the amino acids arginine and glycine. More...
It is carried by the blood stream to the brain cells, as well as to the cells that make up the skeletal muscles, the heart, the retina, and various skin tissues.

In order to reach the brain, creatine must be successfully transported across the blood-brain barrier. The blood-brain barrier is a system specifically designed to facilitate the transport of needed metabolites to the brain neurons. In addition, by blocking their entry or facilitating their removal, the blood-brain barrier controls the presence of unnecessary metabolites or toxic substances in the brain.

When creatine reaches the blood-brain barrier, it is picked up by the creatine transporter, a member of a large family of sodium-dependent neurotransmitter and amino acid transporters, and moved across the endothelium into the brain tissues. In brain tissue, creatine is selected by the high affinity neuronal plasma membrane creatine transporter and transferred into the brain cells (neurons and glia cells). This transfer of creatine is one directional and occurs against a significant creatine concentration inside the neurons and glia cells.

Investigators at the University of Auckland (New Zealand) used the high-resolution structure of a prokaryotic homologue of the creatine transporter, LeuT, to design a study into this protein's fine structure. They reported in the May 25, 2007, issue of the Journal of Biological Chemistry that combinations of two or three amino acid substitutions at four selected positions resulted in the loss of creatine transport activity and gain of a specific gamma-aminobutyric acid (GABA) transport function. The gained GABA transport capability could be blocked using standard GABA inhibitors.

"This research is very exciting and should lead us to greater understanding of how neural signals are transmitted,” said Dr. David Christie, associate professor of biological sciences at the University of Auckland. "We are gradually learning more about the brain, how it works and regulates itself, and we hope that this knowledge can be translated to treat develop treatments for human neurodegenerative diseases.”


Related Links:
University of Auckland

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.